Literature DB >> 21845393

Catastrophic antiphospholipid syndrome: first signs in the neonatal period.

Marta Cabral1, Clara Abadesso, Marta Conde, Helena Almeida, Helena Carreiro.   

Abstract

The term "catastrophic" antiphospholipid syndrome (CAPS) is used to define a subset of the antiphospholipid syndrome (APS) characterized by the clinical evidence of three or more organ involvement by thrombotic events in a short period of time and with laboratory confirmation of the presence of antiphospholipid antibodies. We describe a male infant first admitted at 17 days old for necrotizing enteritis complicated by cardiac and renal failure. Because of progressive renal function deterioration, a renal biopsy was performed at 8 months old, and histopathologic examination was compatible with renal venous thrombosis. Laboratory searching for vascular, prothrombotic, and metabolic disease was negative. Five months later, he developed two different episodes (20-day range) of ischemic stroke. Genetic test for thrombophilic conditions was positive for two different mutations, and repeatedly high titers of lupus anticoagulant, anticardiolipin, and anti-β2glicoprotein I antibodies were found. He was treated successfully with anticoagulants and showed a favorable clinical evolution. To the best of our knowledge, this is the youngest patient reported with probable CAPS. Although rare, APS/CAPS in the neonatal period or in the first year of life must be suspected in infants presenting with thrombotic phenomena. The present case illustrates the importance of an early diagnosis and treatment to enhance possibilities of survival.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21845393     DOI: 10.1007/s00431-011-1548-9

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  21 in total

1.  The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome.

Authors:  Ilan Krause; Miri Blank; Abigail Fraser; Margalit Lorber; Ludmilla Stojanovich; Josef Rovensky; Yehuda Shoenfeld
Journal:  Immunobiology       Date:  2005-10-21       Impact factor: 3.144

2.  Infant with probable catastrophic antiphospholipid syndrome successfully managed with rituximab.

Authors:  Estibaliz Iglesias-Jiménez; Marisol Camacho-Lovillo; Dolores Falcón-Neyra; Jose Lirola-Cruz; Olaf Neth
Journal:  Pediatrics       Date:  2010-05-17       Impact factor: 7.124

Review 3.  The catastrophic antiphospholipid (Asherson's) syndrome in 2004--a review.

Authors:  Ronald A Asherson
Journal:  Autoimmun Rev       Date:  2005-01       Impact factor: 9.754

4.  The "primary" antiphospholipid syndrome: major clinical and serological features.

Authors:  R A Asherson; M A Khamashta; J Ordi-Ros; R H Derksen; S J Machin; J Barquinero; H H Outt; E N Harris; M Vilardell-Torres; G R Hughes
Journal:  Medicine (Baltimore)       Date:  1989-11       Impact factor: 1.889

Review 5.  Antiphospholipid syndrome and the kidneys.

Authors:  Imad Uthman; Munther Khamashta
Journal:  Semin Arthritis Rheum       Date:  2006-06       Impact factor: 5.532

Review 6.  Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations.

Authors:  T Avcin; R Cimaz; P L Meroni
Journal:  Lupus       Date:  2002       Impact factor: 2.911

Review 7.  Antiphospholipid syndrome: pathogenic mechanisms.

Authors:  Gerard Espinosa; Ricard Cervera; Josep Font; Yehuda Shoenfeld
Journal:  Autoimmun Rev       Date:  2003-03       Impact factor: 9.754

8.  Evaluation of clinical and laboratory features of antiphospholipid syndrome: a retrospective study of 637 patients.

Authors:  P Soltész; K Veres; G Lakos; E Kiss; L Muszbek; G Szegedi
Journal:  Lupus       Date:  2003       Impact factor: 2.911

9.  Outcome of primary antiphospholipid syndrome in childhood.

Authors:  M Gattorno; F Falcini; A Ravelli; F Zulian; A Buoncompagni; G Martini; M Resti; P Picco; A Martini
Journal:  Lupus       Date:  2003       Impact factor: 2.911

10.  Long term outcome of catastrophic antiphospholipid syndrome survivors.

Authors:  D Erkan; R A Asherson; G Espinosa; R Cervera; J Font; J-C Piette; M D Lockshin
Journal:  Ann Rheum Dis       Date:  2003-06       Impact factor: 19.103

View more
  3 in total

1.  Pediatric APS: State of the Art.

Authors:  Arzu Soybilgic; Tadej Avcin
Journal:  Curr Rheumatol Rep       Date:  2020-03-03       Impact factor: 4.592

Review 2.  Clinical, laboratory, and therapeutic analyses of 21 patients with neonatal thrombosis and antiphospholipid antibodies: a literature review.

Authors:  Marcus Vinicius da Costa Peixoto; Jozélio Freire de Carvalho; Carlos Ewerton Maia Rodrigues
Journal:  J Immunol Res       Date:  2014-07-17       Impact factor: 4.818

3.  Case Report: Infantile Ischemic Stroke and Antiphospholipid Antibodies, Description of Four Cases.

Authors:  Teresa Giani; Angela Mauro; Giovanna Ferrara; Rolando Cimaz
Journal:  Front Pediatr       Date:  2020-11-24       Impact factor: 3.418

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.